These early-stage drug discovery companies, Quixgen and API Pharma Tech, join nearly two dozen other life sciences businesses that currently call CCIT home.
“CCIT has welcomed over 40 emerging life sciences companies since 2010,” EDA Chief Executive Officer Melissa Orsen said. “CCIT provides the tools, support and connections that growing companies need to thrive in the Garden State, and we are pleased to welcome Quixgen and API Pharma Tech.”
Strategically located in the heart of the State’s research corridor between Rutgers and Princeton universities, CCIT offers the most wet labs of any incubator in New Jersey. The incubator includes both small and large labs, as well as offices.
Quixgen founders Yusheng Xiong and Hong-Ping Guan spent over two decades at New Jersey-based pharmaceutical giant Merck before launching their company.
They leased an 800-square-foot lab at CCIT, where Quixgen will focus on finding a niche in the drug discovery/infectious diseases market. When @NJEDATech spoke with Xiong about his arrival at CCIT, he spoke highly about the infrastructure of the lab and was already impressed with the atmosphere of the tenants and the opportunities he will have to engage with founders of other tenant companies.
Christopher Newton, founder of API Pharma Tech, moved to New Jersey from India in 2003 and became a partner and the chief scientific operator at Navinta LLC, a pharmaceutical company based in Ewing.
In 2011, Newton founded Dr Newtons Pharma Solutions, an independent pharmaceutical consulting company based in Plainsboro, before establishing API Pharma Tech earlier this year.
API Pharma Tech is a research-based pharmaceutical company that aims to help clients reduce research and development costs and deliver medicine to treat unmet needs.
The company will develop and deliver products that are expected to meet the needs of people suffering from iron-dependent Anemia, chronic kidney disease, Wilson’s disease, cystine urea kidney stones, and rheumatoid arthritis.